• 1
    Stuart-Harris CH, Schild GC, Oxford JS. Influenza: The Viruses and the Disease. London: Edward Arnold, 1985.
  • 2
    Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:50865096.
  • 3
    Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med 2000; 51:407421.
  • 4
    Hampson AW. Influenza virus antigens and ‘antigenic drift’; in PotterCW (ed): Influenza (Perspectives in Medical Virology). Amsterdam: Elsevier Science, 2002.
  • 5
    Ghedin E, Sengamalay NA, Shumway M et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005; 437:11621166.
  • 6
    Scholtissek C. Pandemic influenza: antigenic shift; in PotterCW (ed): Influenza (Perspectives in Medical Virology). Amsterdam: Elsevier Science, 2002.
  • 7
    Martin V, Sims L, Lubroth J, Pfeiffer D, Slingenbergh J, Domenech J. Epidemiology and ecology of highly pathogenic avian influenza with particular emphasis on South East Asia. Dev Biol 2006; 124:2336.
  • 8
  • 9
    Fedson DS, Hirota Y, Shin HK et al. Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997; 15:15061511.
  • 10
    Emanuel EJ, Wertheimer A. Public health. Who should get influenza vaccine when not all can? Science 2006; 312:854855.
  • 11
    Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:17761779.
  • 12
    Brown F, Haaheim LR, Wood JM, Schild GC (ed). Laboratory Correlates of Immunity to Influenza – A Reassessment. Basel: Karger, 2002.
  • 13
    Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373378.
  • 14
    Skehel JJ, Schild GC. The polypeptide composition of influenza A viruses. Virology 1971; 44:396408.
  • 15
    Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998; 16:10091015.
  • 16
    Recommended composition of influenza virus vaccines for use in the 2005 influenza season. Wkly Epidemiol Rec 2004; 79:369373.
  • 17
    Musiychuk K, Stephenson N, Bi H et al. A launch vector for the production of vaccine antigens in plants. Influenza 2007; 1:1925.
  • 18
    Goldenkova IV, Musiichuk KA, Piruzian ES. A thermostable Clostridium thermocellum lichenase-based reporter system for studying the gene expression regulation in prokaryotic and eukaryotic cells. Mol Biol 2002; 36:868876.
  • 19
    Sweet C, Smith H. Pathogenicity of influenza virus. Microbiol Rev 1980; 44:303330.
  • 20
    Gjetting T, Carver TL, Skot L, Lyngkjaer MF. Differential gene expression in individual papilla-resistant and powdery mildew-infected barley epidermal cells. Mol Plant Microbe Interact 2004; 17:729738.
  • 21
    World Health Organization. WHO Animal Influenza Manual. [accessed 27 January 2008].
  • 22
    Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937943.
  • 23
    Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982; 146:780790.
  • 24
    Chichester JA, Musiychuk K, De La Rosa P et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007; 25:31113114.
  • 25
    Mett V, Lyons J, Musiychuk K et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 2007; 25:30143017.
  • 26
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 1972; 70:767777.
  • 27
    Potter CW, Shore SL, McLaren C, Stuart-Harris C. Immunity to influenza in ferrets. II. Influence of adjuvants on immunization. Br J Exp Pathol 1972; 53:168179.
  • 28
    Potter CW, McLaren C, Shore SL. Immunity to influenza in ferrets. V. Immunization with inactivated virus in adjuvant 65. J Hyg 1973; 71:97106.
  • 29
    Potter CW, Jennings R, McLaren C. Immunity to influenza in ferrets. VI. Immunization with adjuvanted vaccines. Arch Gesamte Virusforsch 1973; 42:285296.
  • 30
    Keitel WA, Couch RB. Inactivated influenza vaccines; in PotterCW (ed): Influenza (Perspectives in Medical Virology). Amsterdam: Elsevier, 2002.
  • 31
    Brown F, Roberstson JS, Schild G, Wood JM (ed). Inactivated Influenza Vaccines Prepared in Cell Culture. Basel: Karger, 1997.
  • 32
    Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol 2004; 78:18511857.
  • 33
    Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev 2004; 2:842847.
  • 34
    Treanor JJ, Schiff GM, Couch RB et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006; 193:12231228.